<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="140419">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01272960</url>
  </required_header>
  <id_info>
    <org_study_id>SFP4-13</org_study_id>
    <nct_id>NCT01272960</nct_id>
  </id_info>
  <brief_title>Mirena Intrauterine System Timing of Insertion: A Randomized Controlled Trial</brief_title>
  <acronym>MISTIC</acronym>
  <official_title>Randomized, Open-label, Controlled Trial of Immediate Postpartum Versus Interval Insertion of Mirena to Increase the Usage at 6 Months After Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to determine the timing of LNG-IUS insertion that results in a greater proportion
      of women using the LNG-IUS at 6-months post-partum, we will perform a randomized control
      trial of interval versus immediate post-placenta insertion. Women will be enrolled at
      36-weeks gestation and greater. At the time of vaginal delivery, women will be randomized to
      receive either immediate post-placenta insertion of the LNG-IUS or routine insertion at 4-8
      weeks post-partum. All patients will return at 4-6 weeks post-insertion and 6 months
      post-partum to confirm correct position of the LNG-IUS. The primary outcome of this
      sub-study is the number of LNG-IUS in the correct position at 6-months. Secondary outcomes
      include assessing the safety of post-placental LNG-IUS insertion and difference in
      acceptability and symptoms experienced by participants. This is a sub-study of the
      Contraceptive Choice Project, a prospective cohort study that aims to improve the use of
      long-acting contraception by removing financial barriers which has already enrolled over
      5,000 patients. Association of this study with CHOICE offers unique advantages including
      infrastructure to support subject recruitment, retention and completion of follow-up as well
      as covering the cost of LNG-IUS devices.

      We hypothesize that, despite higher expulsion rates, women randomized to receive the LNG-IUS
      immediately after placenta delivery will have higher rates of LNG-IUS continuation due to
      poor rates of follow up in the interval insertion group. This is likely to be particularly
      noticeable in our patient population, which is largely uninsured with poor access to
      healthcare. Further, typical symptoms of LNG-IUS insertion include bleeding and cramping,
      which may be disguised by the post-partum period. Published reports of immediate
      post-placenta insertion focus on expulsion rates and do not report on symptoms and
      satisfaction rates.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mirena in place</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of women in each arm with Mirena in place at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mirena expulsion</measure>
    <time_frame>6 weeks</time_frame>
    <description>The percentage of patients with post-placental placement of Mirena who experience an expulsion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine perforation</measure>
    <time_frame>6 months</time_frame>
    <description>The proportion of patients in each arm who experience a uterine perforation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrauterine infection</measure>
    <time_frame>6 months</time_frame>
    <description>The proportion of patients in each arm who experience an intrauterine infection (endometritis, pelvic inflammatory disease)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Postpartum Period</condition>
  <arm_group>
    <arm_group_label>Interval Insertion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive Mirena at 4-8 weeks post-partum after vaginal delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-Placental Mirena Insertion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive Mirena insertion within 10 minutes of delivery of placenta</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Post-Placenta Mirena Insertion</intervention_name>
    <description>Mirena(R) intrauterine device will be inserted within 10 minutes of delivery of the placenta</description>
    <arm_group_label>Interval Insertion</arm_group_label>
    <arm_group_label>Post-Placental Mirena Insertion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  14-45 years

          -  Vaginal Delivery at Barnes-Jewish Hospital

          -  Sexually active with male partner

          -  No tubal ligation/hysterectomy

          -  Not currently using contraception

          -  Desire reversible contraception

          -  Reside in St. Louis City/County

          -  Requests Mirena(R) intrauterine device for contraception

        Exclusion Criteria:

          -  Allergy to Mirena(R) system

          -  Cesarean delivery

          -  Cervical cancer, breast cancer

          -  Active liver disease

          -  Untreated cervicitis

          -  Uterine anomaly/fibroids preventing Mirena(R) placement

          -  Delivery &lt;36 weeks

          -  Chorioamnionitis

          -  Prolonged rupture of membranes (&gt;18 hours)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorie M Harper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health. 2006 Jun;38(2):90-6.</citation>
    <PMID>16772190</PMID>
  </reference>
  <reference>
    <citation>Gillett PG, Lee NH, Yuzpe AA, Cerskus I. A comparison of the efficacy and acceptability of the Copper-7 intrauterine device following immediate or delayed insertion after first-trimester therapeutic abortion. Fertil Steril. 1980 Aug;34(2):121-4.</citation>
    <PMID>7409230</PMID>
  </reference>
  <reference>
    <citation>Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril. 1994 Jan;61(1):70-7.</citation>
    <PMID>8293847</PMID>
  </reference>
  <reference>
    <citation>Comparative multicentre trial of three IUDs inserted immediately following delivery of the placenta. Contraception. 1980 Jul;22(1):9-18.</citation>
    <PMID>7418410</PMID>
  </reference>
  <reference>
    <citation>Thiery M, Van Kets H, Van der Pas H. Immediate post-placental IUD insertion: the expulsion problem. Contraception. 1985 Apr;31(4):331-49.</citation>
    <PMID>4006467</PMID>
  </reference>
  <reference>
    <citation>Morrison C, Waszak C, Katz K, Diabaté F, Mate EM. Clinical outcomes of two early postpartum IUD insertion programs in Africa. Contraception. 1996 Jan;53(1):17-21.</citation>
    <PMID>8631184</PMID>
  </reference>
  <reference>
    <citation>Xu JX, Reusché C, Burdan A. Immediate postplacental insertion of the intrauterine device: a review of Chinese and the world's experiences. Adv Contracept. 1994 Mar;10(1):71-82. Review.</citation>
    <PMID>8030457</PMID>
  </reference>
  <reference>
    <citation>Zhou SW, Chi IC. Immediate postpartum IUD insertions in a Chinese hospital--a two year follow-up. Int J Gynaecol Obstet. 1991 Jun;35(2):157-64.</citation>
    <PMID>1680090</PMID>
  </reference>
  <reference>
    <citation>Eroğlu K, Akkuzu G, Vural G, Dilbaz B, Akin A, Taşkin L, Haberal A. Comparison of efficacy and complications of IUD insertion in immediate postplacental/early postpartum period with interval period: 1 year follow-up. Contraception. 2006 Nov;74(5):376-81. Epub 2006 Sep 15.</citation>
    <PMID>17046378</PMID>
  </reference>
  <reference>
    <citation>Chen BA, Reeves MF, Hayes JL, Hohmann HL, Perriera LK, Creinin MD. Postplacental or delayed insertion of the levonorgestrel intrauterine device after vaginal delivery: a randomized controlled trial. Obstet Gynecol. 2010 Nov;116(5):1079-87. doi: 10.1097/AOG.0b013e3181f73fac.</citation>
    <PMID>20966692</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>January 6, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contraception</keyword>
  <keyword>Postnatal care</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
